1. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
    Se Kim et al, 2018, International Journal of Molecular Sciences CrossRef
  2. Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
    Giovanni Schinzari et al, 2018, Oncotarget CrossRef
  3. Use of oral paclitaxel for the treatment of bladder tumors in dogs
    Hyung-Kyu CHAE et al, 2020, Journal of Veterinary Medical Science CrossRef
  4. Medical Image Diagnostic Value of Computed Tomography for Bladder Tumors
    Lin Li et al, 2021, Computational and Mathematical Methods in Medicine CrossRef
  5. Systemic treatment options in bladder cancer
    Vanita Noronha et al, 2018, Cancer Research, Statistics, and Treatment CrossRef
  6. ABT-751 Induces Multiple Anticancer Effects in Urinary Bladder Urothelial Carcinoma-Derived Cells: Highlighting the Induction of Cytostasis through the Inhibition of SKP2 at Both Transcriptional and Post-Translational Levels
    Seyedeh Zahra Dehghanian et al, 2021, International Journal of Molecular Sciences CrossRef
  7. Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
    Qinghai Zeng et al, 2018, Clinical Cancer Research CrossRef
  8. Modern possibilities of organ-preserving treatment of patients with muscle-invasive bladder cancer
    Vladimir J. Startsev et al, 2019, Urologicheskie vedomosti CrossRef
  9. Bladder Cancer
    Surya K. De, 2022, Fundamentals of Cancer Detection, Treatment, and Prevention CrossRef
  10. TiO2 Nanoparticles in Cancer Therapy as Nanocarriers in Paclitaxel’s Delivery and Nanosensitizers in Phototherapies and/or Sonodynamic Therapy
    Fernanda M.P. Tonelli et al, 2023, Current Pharmaceutical Biotechnology CrossRef
  11. Analysis of long non-coding RNAs associated with disulfidptosis for prognostic signature and immunotherapy response in uterine corpus endometrial carcinoma
    Bohan Li et al, 2023, Scientific Reports CrossRef
  12. Emerging agents for the treatment of metastatic urothelial cancer
    Whi-An Kwon et al, 2021, Investigative and Clinical Urology CrossRef
  13. A ‘golden’ alternative for prevention of cisplatin nephrotoxicity in bladder cancer
    Yoray Sharon et al, 2023, Cancer Nanotechnology CrossRef
  14. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma
    Yuji Takeyama et al, 2018, International Journal of Clinical Oncology CrossRef
  15. Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin
    Susanne Deininger et al, 2021, Cancers CrossRef
  16. Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy
    Yumeng Wei et al, 2017, Oncology Reports CrossRef
  17. A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma
    Kai Xie et al, 2024, Cancer Biomarkers CrossRef
  18. Pseudoprogression or unexpected favorable response to third-line therapy: a challenging metastatic bladder cancer case
    Adriana Soares et al, 2020, Porto Biomedical Journal CrossRef
  19. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework
    Songyun Zhao et al, 2023, Frontiers in Endocrinology CrossRef
  20. Gold nanoparticles for safe delivery of cisplatin
    Yoray Sharon et al, 2024, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XXI CrossRef
  21. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
    Nataliya Mar et al, 2023, Cancers CrossRef
  22. Leveraging a gene signature associated with disulfidptosis identified by machine learning to forecast clinical outcomes, immunological heterogeneities, and potential therapeutic targets within lower-grade glioma
    Yao Zhou et al, 2023, Frontiers in Immunology CrossRef
  23. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study
    Xi Chen et al, 2023, Medicine CrossRef
  24. Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma
    Li Yang et al, 2023, Melanoma Management CrossRef

  25. Review of Curcumin Physicochemical Targeting Delivery System


    Lanmei Li et al, 2020, International Journal of Nanomedicine CrossRef